Salud financiera de hoja de balance de Alpine Immune Sciences
Salud financiera controles de criterios 6/6
Alpine Immune Sciences tiene un patrimonio de los accionistas total de $327.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $379.9M y $51.9M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$327.41m |
| Patrimonio | US$327.94m |
| Total pasivo | US$51.91m |
| Activos totales | US$379.85m |
Actualizaciones recientes sobre salud financiera
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right
Jun 03Alpine Immune Sciences files for $150M mixed shelf offering
May 26Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 29Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($330.0M) de ALPN superan a sus pasivos a corto plazo ($42.0M).
Pasivo a largo plazo: Los activos a corto plazo de ALPN ($330.0M) superan a sus pasivos a largo plazo ($9.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ALPN está libre de deudas.
Reducción de la deuda: ALPN no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 9.4%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ALPN tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ALPN dispone de suficiente cash runway para 2.5 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 18.1% cada año.